Dr. John L. Reagan, MD

Dr. Reagan practices at Rhode Island Hospital/Hasbro Children's in Providence, Rhode Island.

Dr. Reagan's NPI, 1841418944, was assigned on April 23, 2007. Dr. Reagan holds Rhode Island license MD13112.

Dr. Reagan's primary practice is Rhode Island Hospital/Hasbro Children's, at 593 Eddy St, Providence, RI 02903 in Providence County. The practice phone is (401) 444-6966.

Dr. Reagan's primary practice is Rhode Island Hospital/Hasbro Children's in Providence, Rhode Island. Dr. Reagan is also affiliated with The Miriam Hospital. The medical group on file is Rhode Island Hospital. Dmand AI also links Dr. Reagan to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reagan practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Reagan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Reagan is licensed in Rhode Island.

CMS data shows 472 Medicare services from Dr. Reagan across 4 procedure codes in 2024, for 239 Medicare patients. Medicare paid $33,273 for them.

CMS counts 239 Medicare patients who saw Dr. Reagan in 2024. The largest group is 75 to 84, with 103 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reagan's median patient age at 73, with 47% women.

In 2024, Dr. Reagan wrote 1,424 Medicare Part D claims for 176 patients. 67% of them were for generic drugs. CMS names the drug for 1,166 of them, across 33 drugs with 11 or more claims each, at $6,010,878 in total drug cost. In 2023, CMS named 1,077 claims across 31 drugs.

Dr. Reagan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Reagan as offering telehealth.

Dmand AI links 73 papers to Dr. Reagan, published from 2011 to 2025. 2018 was the busiest year, with 9. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Anticoagulants and Cyclophosphamide. Dr. Reagan has published most often in Am J Hematol. Dr. Reagan's most frequent co-authors are James N. Butera, MD, Jorge J. Castillo, MD and Andrew Hsu, MD.

Dmand AI links Dr. Reagan to 4 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Disease Progression and Multiple Myeloma.

CMS Open Payments shows 83 general payments to Dr. Reagan from 14 drug and device companies from 2016 to 2024. Honoraria make up the largest share, 46% of the total. Alexion Pharmaceuticals, Inc. paid the most, $41,255. It also lists 1 research payment totaling $1,463 in 2017.